CHMFL-BMX-078
CAS : 1808288-51-8
Ref. 3D-IXC28851
1mg | Arrêté | ||
2mg | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté |
Informations sur le produit
CHMFL-BMX-078 is a covalent inhibitor that targets the tyrosine kinase of activated cancer cells. It has been shown to be an effective treatment for cancers with activating mutations in the epidermal growth factor receptor (EGFR) gene, such as non-small cell lung cancer and colorectal cancer. CHMFL-BMX-078 has also been used in clinical trials for patients with metastatic solid tumours who have not responded to standard therapy. This drug has also been shown to be safe and tolerable at doses of up to 100 mg/kg per day, with no significant adverse effects.